73 Results

People

  1. Usmani
    Usmani
  2. Landgren
    Landgren
  3. Mailankody
    Mailankody
  4. Giralt
    Giralt
  5. Lesokhin
    Lesokhin
  6. Korde
    Korde
  7. Shah
    Shah
  8. Hassoun
    Hassoun
  9. Landau
    Landau
  10. Hultcrantz
    Hultcrantz

Groups

  1. Department of Medicine (54)
  2. Hematologic Malignancies, Division of (49)
  3. Center for Hematologic Malignancies (44)
  4. Myeloma (31)
  5. Hematologic Malignancies Research (24)
  6. Survivorship Research (20)
  7. Bone Marrow Transplant (17)
  8. CTCR Scholars (12)
  9. Graduate Medical Education (12)
  10. GME, Medicine (11)
  1. "carfilzomib"
Formats
  1. Journal Article (53)
  2. Review (11)
  3. Research Letter (4)
  4. Editorial (2)
  5. Conference Paper (1)
  6. Correspondence (1)
  7. Meeting Abstract (1)
Groups
  1. Department of Medicine (54)
  2. Hematologic Malignancies, Division of (49)
  3. Center for Hematologic Malignancies (44)
  4. Myeloma (31)
  5. Hematologic Malignancies Research (24)
  6. Survivorship Research (20)

More Groups

People
  1. Saad Usmani (16)
  2. Carl Landgren (14)
  3. Sham Mailankody (14)
  4. Alexander Lesokhin (13)
  5. Sergio Giralt (13)
  6. Neha Korde (12)

More People

Years
  1. 2025 (5)
  2. 2024 (15)
  3. 2023 (12)
  4. 2022 (8)
  5. 2021 (5)
  6. 2020 (5)

More Years

Publications
  1. American Journal of Hematology (5)
  2. Blood (5)
  3. Clinical Lymphoma, Myeloma and Leukemia (4)
  4. Blood Advances (3)
  5. Blood Cancer Journal (3)
  6. Best Practice and Research: Clinical Haematology (2)

More Publications

Publishers
  1. Elsevier Inc. (11)
  2. American Society of Hematology (8)
  3. Nature Publishing Group (8)
  4. John Wiley & Sons (6)
  5. John Wiley & Sons, Inc. (5)
  6. Elsevier Science, Inc. (4)

More Publishers

Results (73)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 clinical trial of B-cell maturation antigen (BCMA) NEX-T® chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
    Journal Article

    Ravi, G.; Richard, S.; Kumar, S.; Atrash, S.; Liedtke, M.; Kaur, G.; Derman, B.; Bergsagel, P. L.; Mailankody, S.; McCarthy, P.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • High WEE1 expression is independently linked to poor survival in multiple myeloma
    Journal Article

    Simhal, A. K.; Firestone, R. S.; Oh, J. H.; Avutu, V.; Norton, L.; Hultcrantz, M.; Usmani, S. Z.; Maclachlan, K. H.; Deasy, J. O.
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
    Journal Article

    Bhutani, M.; Robinson, M.; Foureau, D.; Atrash, S.; Paul, B.; Guo, F.; Grayson, J. M.; Ivanina-Foureau, A.; Pineda-Roman, M.; Varga, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Addition of elotuzumab to backbone treatment regimens for multiple myeloma: An updated meta-analysis of randomized clinical trials
    Journal Article

    Costa, B. A.; Costa, T. A.; Chagas, G. C. L.; Mouhieddine, T. H.; Richter, J.; Usmani, S. Z.; Mailankody, S.; Rajeeve, S.; Hashmi, H.
    Clinical Lymphoma, Myeloma and Leukemia (2025)

    Fulltext@MSK | Save
  • Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): Results from a randomised, open-label, phase 3 trial
    Journal Article

    Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L.; Isufi, I.; Harrison, S. J.; Shah, U. A.; more...
    The Lancet Haematology (2025)

    Fulltext@MSK | Save
  • Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis
    Journal Article

    Goel, U.; Dima, D.; Davis, J.; Ahmed, N.; Shaikh, H.; Lochner, J.; Abdallah, A. O.; Khouri, J.; Hashmi, H.; Anwer, F.
    European Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Alliance A061202: Ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse
    Journal Article

    Voorhees, P.; Suman, V.; Efebera, Y.; Raje, N.; Tuchman, S.; Rodriguez, C.; Laubach, J.; Bova-Solem, M.; Carlisle, D.; Usmani, S.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
    Research Letter

    Hultcrantz, M.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; Lahoud, O. B.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
    Editorial

    Rodriguez-Otero, P.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; Vij, R.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
    Journal Article

    Cirrincione, A. M.; Poos, A. M.; Ziccheddu, B.; Kaddoura, M.; Bärtsch, M. A.; Maclachlan, K.; Chojnacka, M.; Diamond, B.; John, L.; Reichert, P.; more...
    Blood (2024)

    Fulltext@MSK | Save